# Novotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novotech

- Industry: Biotechnology
- Headquarters: Sydney, Australia
- Website: www.novotech-cro.com/
- Total disclosed funding: $7.1M
- Latest round: Series A (Nov 1, 2007)
- Investors on record: 2

## About

Based in Sydney, Australia, and founded in 1997, as the Asia Pacific CRO and a subsidiary company of Novotech Health Holdings, Novotech (Australia) Pty Limited, aka Novotech provides clinical development services for biotechnology companies. It has been instrumental in the success of over a thousand Phase I-IV clinical trials. The firm was formerly a venture-backed by BioPacific Partners and North Ridge Partners and invested by Mercury Capital and TPG. In 2020, Novotech and PPC, both majority-owned by private investment shop TPG Capital Asia, merged to form Novotech Health Holdings (Novotech Holdings). Novotech provides clinical development services that offer audits, clinical trials, biostatistics, data processing, medical writing, and regulatory affairs to include clinical research and testing for biotechnology companies. The company is preparing for an initial public offering in Hong Kong later this year.

## Funding rounds

- Series A, Nov 1, 2007, $7.1M — North Ridge Partners, BioPacific Partners

## Investors

- North Ridge Partners (https://capitalatlas.ai/funds/north-ridge-partners) — Series A
- BioPacific Partners (https://capitalatlas.ai/funds/biopacific-partners) — Series A